Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-04-15
DOI
10.3389/fendo.2020.00190
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials
- (2019) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
- (2019) Helena W. Rodbard et al. DIABETES CARE
- Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
- (2019) Hirotaka Watada Journal of Diabetes Investigation
- Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
- (2019) Ildiko Lingvay et al. Lancet Diabetes & Endocrinology
- Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice: The earlier and longer, the better
- (2018) Tomohiko Kimura et al. DIABETES OBESITY & METABOLISM
- Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis
- (2018) Yun Kyung Cho et al. Journal of Diabetes Investigation
- Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
- (2017) Tsung-Ming Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes
- (2017) Michael J. Kraakman et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes
- (2017) Yingying Yang et al. MEDICINE
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization
- (2017) Liang Xu et al. Adipocyte
- SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice
- (2016) Kathryn M. Thrailkill et al. BONE
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
- (2016) Subodh Verma et al. DIABETES CARE
- Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials
- (2016) H. L. Tang et al. DIABETES OBESITY & METABOLISM
- Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis
- (2016) Se Hee Min et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice
- (2016) Atsushi Obata et al. ENDOCRINOLOGY
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice
- (2016) Atsuo Tahara et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
- (2016) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis
- (2016) Maria Lorenzi et al. Diabetes Therapy
- Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis
- (2016) Maria Lorenzi et al. Diabetes Therapy
- Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key β-cell factors under diabetic conditions
- (2015) Naoki Shimo et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- (2015) Silvio E Inzucchi et al. Diabetes & Vascular Disease Research
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
- (2015) Ngozi Erondu et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
- (2015) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Quality of diabetes care in low- and middle-income Asian and Middle Eastern countries (1993–2012) – 20-Year systematic review
- (2015) Roopa Shivashankar et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT inhibition and euglycaemic diabetic ketoacidosis
- (2015) Julia Hine et al. Lancet Diabetes & Endocrinology
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin
- (2014) Beverley Balkau et al. DIABETES CARE
- Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
- (2014) Bruce Neal et al. DIABETES CARE
- Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
- (2014) Julio Rosenstock et al. DIABETES CARE
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- (2014) Raymond V. Oliva et al. Journal of the American Society of Hypertension
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
- (2014) Michael Nauck Drug Design Development and Therapy
- Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
- (2014) Yasong Lu et al. Frontiers in Pharmacology
- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
- (2013) John P.H. Wilding ANNALS OF INTERNAL MEDICINE
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010
- (2013) S. Stark Casagrande et al. DIABETES CARE
- Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
- (2013) J. P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Cellular Mechanisms by Which FGF21 Improves Insulin Sensitivity in Male Mice
- (2013) João Paulo G. Camporez et al. ENDOCRINOLOGY
- M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and nonalcoholic fatty liver disease
- (2013) Jinghong Wan et al. HEPATOLOGY
- Association between Serum Leptin Concentrations and Insulin Resistance: A Population-Based Study from China
- (2013) Hui Zuo et al. PLoS One
- Role of leptin and adiponectin in insulin resistance
- (2012) Amita Yadav et al. CLINICA CHIMICA ACTA
- Why Do SGLT2 Inhibitors Inhibit Only 30-50% of Renal Glucose Reabsorption in Humans?
- (2012) J. Liu et al. DIABETES
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Adaptive immunity in obesity and insulin resistance
- (2012) Henrike Sell et al. Nature Reviews Endocrinology
- Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats
- (2012) James J. Devenny et al. Obesity
- SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
- (2011) Michael J. Jurczak et al. DIABETES
- Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis
- (2011) A. E. Pontiroli et al. DIABETES OBESITY & METABOLISM
- Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance
- (2009) A. O. Chavez et al. DIABETES CARE
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity
- (2009) Satoshi Nishimura et al. NATURE MEDICINE
- Ablation of CD11c-Positive Cells Normalizes Insulin Sensitivity in Obese Insulin Resistant Animals
- (2008) David Patsouris et al. Cell Metabolism
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started